Indo Us Biotech LimitedQ2 FY27 Results & Financial Update
Indo Us Biotech Limited: Q2 FY27 standalone results and company financials – revenue ₹15.05 Cr, PAT ₹-3.67 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Indo Us Biotech price & chart
Market price₹73.54
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Indo Us Biotech Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Indo Us Biotech Limited reported a standalone operational revenue of INR 15.05 crore for the quarter ended September 30, 2026, alongside total income of INR 15.10 crore.
The business experienced a net loss of INR 3.67 crore during Q2 FY27, accompanied by a negative profit before tax (PBT) of INR 3.65 crore.
Basic and diluted earnings per share (EPS) stood at a negative INR 1.83 for the quarter.
Total expenses for the period included finance costs of INR 0.81 crore, depreciation and amortisation charges of INR 0.28 crore, and provisions amounting to INR 0.03 crore.
Tax expense for the quarter was recorded at INR 0.02 crore, while other income contributed INR 0.05 crore to the standalone financial results.
Sequential comparisons indicate a contraction in profitability relative to the preceding quarter ended June 30, 2026, driven by operating cost structures relative to revenue generation.
The statutory filing provides standalone figures without providing year-ago comparative figures in this specific electronic filing structure.
01 · Business model
What does Indo Us Biotech do?
Indo Us Biotech Limited operates in the agricultural biotechnology and seed production sector, focusing on the research, development, processing, and marketing of high-yielding crop seeds.
The company serves agricultural communities by supplying diverse hybrid and open-pollinated seed varieties designed to improve crop resilience and farm yields.
Its operational footprint encompasses seed processing facilities, distribution networks, and agricultural research collaborations aimed at meeting seasonal farming demands across target domestic markets.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹15.05 Cr | ₹32.99 Cr |
| Total income | ₹15.10 Cr | ₹33.11 Cr |
| Profit before tax | ₹-3.65 Cr | ₹3.08 Cr |
| Profit after tax | ₹-3.67 Cr | ₹3.04 Cr |
| EPS | ₹-1.83 | ₹1.51 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -24.4% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -24.2% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.05 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Reported standalone revenue from operations reached INR 15.05 crore for Q2 FY27.
Total income reached INR 15.10 crore, supported by INR 0.05 crore in other income alongside core operational revenue.
What drove margins
Finance costs stood at INR 0.81 crore for the quarter, exerting pressure on bottom-line profitability.
Depreciation and amortisation expenses were recorded at INR 0.28 crore for Q2 FY27.
04 · Pressure points & risks
What is not going smoothly
The company posted a net loss of INR 3.67 crore for the quarter ended September 30, 2026.
05 · Items worth noticing
The line items that can distort a quick read
The company recorded provisions amounting to INR 0.03 crore during the quarter.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory Filing Scope
The financial results for Q2 FY27 were submitted as a standalone structured filing via stock exchange channels.
07 · Key Q&A
The quarter, answered directly
What does Indo Us Biotech do?
Indo Us Biotech Limited operates in the agricultural biotechnology and seed production sector, focusing on the research, development, processing, and marketing of high-yielding crop seeds.
What is the clearest takeaway from Q2 FY27?
Indo Us Biotech Limited reported a standalone operational revenue of INR 15.05 crore for the quarter ended September 30, 2026, alongside total income of INR 15.10 crore.
What drove revenue or demand?
Reported standalone revenue from operations reached INR 15.05 crore for Q2 FY27.
What mattered most for margins or profitability?
Finance costs stood at INR 0.81 crore for the quarter, exerting pressure on bottom-line profitability.
What changed operationally beyond the headline numbers?
The financial results for Q2 FY27 were submitted as a standalone structured filing via stock exchange channels.
What are the main pressure points disclosed for the quarter?
The company posted a net loss of INR 3.67 crore for the quarter ended September 30, 2026.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Financials: Monitor upcoming quarterly disclosures to track revenue recovery and operational cost trends.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.